Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 60

1.

The role of tumour-stromal interactions in modifying drug response: challenges and opportunities.

McMillin DW, Negri JM, Mitsiades CS.

Nat Rev Drug Discov. 2013 Mar;12(3):217-28. doi: 10.1038/nrd3870. Review.

PMID:
23449307
2.

Mouse tumour models to guide drug development and identify resistance mechanisms.

Das Thakur M, Pryer NK, Singh M.

J Pathol. 2014 Jan;232(2):103-11. doi: 10.1002/path.4285. Review.

PMID:
24122209
3.

Regulation of tumor-stromal fibroblast interactions: implications in anticancer therapy.

Kiaris H, Trimis G, Papavassiliou AG.

Curr Med Chem. 2008;15(29):3062-7. Review.

PMID:
19075653
4.
5.
6.

The role of stromal fibroblasts in lung carcinogenesis: A target for chemoprevention?

Mahale J, Smagurauskaite G, Brown K, Thomas A, Howells LM.

Int J Cancer. 2016 Jan 1;138(1):30-44. doi: 10.1002/ijc.29447. Epub 2015 Feb 6. Review.

7.

Towards the use of cannabinoids as antitumour agents.

Velasco G, Sánchez C, Guzmán M.

Nat Rev Cancer. 2012 May 4;12(6):436-44. doi: 10.1038/nrc3247. Review.

PMID:
22555283
8.

Microfluidic 3D models of cancer.

Sung KE, Beebe DJ.

Adv Drug Deliv Rev. 2014 Dec 15;79-80:68-78. doi: 10.1016/j.addr.2014.07.002. Epub 2014 Jul 10. Review.

9.

Targeting the tumor microenvironment: from understanding pathways to effective clinical trials.

Fang H, Declerck YA.

Cancer Res. 2013 Aug 15;73(16):4965-77. doi: 10.1158/0008-5472.CAN-13-0661. Epub 2013 Aug 2. Review.

10.

Pathophysiologically relevant in vitro tumor models for drug screening.

Das V, Bruzzese F, Konečný P, Iannelli F, Budillon A, Hajdúch M.

Drug Discov Today. 2015 Jul;20(7):848-55. doi: 10.1016/j.drudis.2015.04.004. Epub 2015 Apr 20. Review.

PMID:
25908576
11.

Harnessing synthetic lethal interactions in anticancer drug discovery.

Chan DA, Giaccia AJ.

Nat Rev Drug Discov. 2011 May;10(5):351-64. doi: 10.1038/nrd3374. Review.

12.

Drug screening in 3D in vitro tumor models: overcoming current pitfalls of efficacy read-outs.

Santo VE, Rebelo SP, Estrada MF, Alves PM, Boghaert E, Brito C.

Biotechnol J. 2017 Jan;12(1). doi: 10.1002/biot.201600505. Epub 2016 Dec 14. Review.

PMID:
27966285
13.

Cytokines in cancer drug resistance: Cues to new therapeutic strategies.

Jones VS, Huang RY, Chen LP, Chen ZS, Fu L, Huang RP.

Biochim Biophys Acta. 2016 Apr;1865(2):255-65. doi: 10.1016/j.bbcan.2016.03.005. Epub 2016 Mar 16. Review.

14.

Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery.

Bouzin C, Feron O.

Drug Resist Updat. 2007 Jun;10(3):109-20. Epub 2007 Apr 23. Review.

PMID:
17452119
15.

Tumours can adapt to anti-angiogenic therapy depending on the stromal context: lessons from endothelial cell biology.

van Kempen LC, Leenders WP.

Eur J Cell Biol. 2006 Feb;85(2):61-8. Epub 2005 Nov 11. Review.

PMID:
16439306
16.

[Tumor microenvironment and therapeutic resistance process].

Borriello L, DeClerck YA.

Med Sci (Paris). 2014 Apr;30(4):445-51. doi: 10.1051/medsci/20143004021. Epub 2014 May 5. Review. French.

17.

The microenvironment of the tumour-host interface.

Liotta LA, Kohn EC.

Nature. 2001 May 17;411(6835):375-9. Review.

PMID:
11357145
18.

Tumour-initiating cells: challenges and opportunities for anticancer drug discovery.

Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB.

Nat Rev Drug Discov. 2009 Oct;8(10):806-23. doi: 10.1038/nrd2137. Review.

PMID:
19794444
19.

Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery.

Ruggeri BA, Camp F, Miknyoczki S.

Biochem Pharmacol. 2014 Jan 1;87(1):150-61. doi: 10.1016/j.bcp.2013.06.020. Epub 2013 Jun 28. Review.

PMID:
23817077
20.

Environment-mediated drug resistance: a major contributor to minimal residual disease.

Meads MB, Gatenby RA, Dalton WS.

Nat Rev Cancer. 2009 Sep;9(9):665-74. doi: 10.1038/nrc2714. Epub 2009 Aug 20. Review.

PMID:
19693095

Supplemental Content

Support Center